Liposomal doxorubicin: all 237 studies that test it

Page 2 of 3. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder CancerStatus unknownNCT04101812Phase 2
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.Status unknownNCT04077905Phase 3
• Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast CancerStatus unknownNCT03994107Phase 1/2
• Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingNCT03971409Phase 2
• Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03952572Phase 3
• Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)Status unknownNCT03949634Phase 3
• Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast CancerStatus unknownNCT03933319Phase 2
• Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue SarcomaStatus unknownNCT03880695Phase 2
• Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian CancerStatus unknownNCT03794778Phase 4
• A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedNCT03719326Phase 1
• CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCERActive, not recruitingNCT03712956Phase 2
• A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.CompletedNCT03681548Phase 1
• Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT03639246Phase 1
• Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian CancerCompletedNCT03596281Phase 1
• Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
• Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsStatus unknownNCT03509246Phase 2
• PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid CarcinomaStatus unknownNCT03387943Phase 2
• TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid TumorsTerminatedNCT03387917Phase 1
• Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast CancerStatus unknownNCT03359694Phase 3
• Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaWithdrawnNCT03342300Phase 2/3
• Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian CancerStatus unknownNCT03335241Phase 2
• Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast CancerCompletedNCT03221881Not applicable
• Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer PatientsStatus unknownNCT03123770Phase 4
• Metronomic PLD in Patients With Primary Endocrine Resistant ABCStatus unknownNCT03071926Phase 2
• A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast CancerCompletedNCT03017404Not applicable
• Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant ChemotherapyStatus unknownNCT02953184Phase 2
• L-DEP as an Initial Treatment for EBV-HLHStatus unknownNCT02912702Phase 3
• Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast CancerStatus unknownNCT02903524Phase 4
• Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant CancerCompletedNCT02751918Phase 1
• Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi SarcomaActive, not recruitingNCT02659930Phase 1
• Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)Active, not recruitingNCT02584478Phase 3
• HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid TumorsWithdrawnNCT02557854Phase 1
• Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular CarcinomaWithdrawnNCT02527772Phase 2/3
• A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast CancerCompletedNCT02488564Phase 2
• R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell LymphomaStatus unknownNCT02428751Phase 3
• Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid TumorsCompletedNCT02262455Phase 1
• Bioequivalence Study of Doxorubicin Hydrochloride Liposome InjectionCompletedNCT02260544Phase 1
• Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian CancerCompletedNCT02237690Phase 1
• Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
• A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerTerminatedNCT02131506Phase 1
• A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian CancerCompletedNCT02081495Phase 1
• Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal CancerActive, not recruitingNCT01970722Phase 1
• 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast CancerCompletedNCT01935492Phase 3
• Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01902225Phase 1
• A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian CancerStatus unknownNCT01715168Phase 1
• Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the PlatinumCompletedNCT01705158Phase 1/2
• Anti-EGFR Immunoliposomes in Solid TumorsCompletedNCT01702129Phase 1
• Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerCompletedNCT01673217Phase 1
• Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast CancerCompletedNCT01669239Phase 2
• ErbB2 Positive Metastatic Breast CancerTerminatedNCT01658358Phase 1/2
• Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple MyelomaStatus unknownNCT01541332Phase 1/2
• Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaWithdrawnNCT01492881Phase 2
• Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or LymphomasWithdrawnNCT01490047Phase 1
• EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01489371Phase 1
• Doxorubicin + BIBF 1120 in Patients for Ovarian CancerTerminatedNCT01485874Phase 1
• Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT01459380Phase 1
• Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast CancerStatus unknownNCT01451580Phase 2
• Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)WithdrawnNCT01333423Phase 1
• TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerCompletedNCT01294293Phase 1
• A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic CancerCompletedNCT01281514Phase 1
• MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)TerminatedNCT01227941Phase 1
• A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer PatientsStatus unknownNCT01210768Phase 2
• Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast CancerCompletedNCT01206881Phase 2
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian CancerTerminatedNCT01202890Phase 1
• Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerCompletedNCT01145430Phase 1
• Myocet Plus Endoxan for Older Patients With Breast CancerTerminatedNCT01120171Phase 2
• A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)TerminatedNCT01110603Phase 1
• F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast CancerCompletedNCT00992706Phase 3
• Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast CancerCompletedNCT00960336Phase 2
• Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed GlioblastomaCompletedNCT00944801Phase 1/2
• Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural MesotheliomaStatus unknownNCT00886028Phase 2
• Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-typeCompletedNCT00861120Phase 2
• Pharmacokinetic Study of Avastin and Doxil in Ovarian CancerCompletedNCT00846612Phase 1
• AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid TumoursTerminatedNCT00819221Phase 1
• Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal TumorsCompletedNCT00815945Phase 2
• My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid LeukemiaStatus unknownNCT00801580Phase 2
• Doxil, Bevacizumab and Temsirolimus TrialCompletedNCT00761644Phase 1
• Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian CarcinomaTerminatedNCT00758732Phase 2
• Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00744354Phase 1
• Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT00742404Phase 2
• A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2
• Phase I Study of DOXIL and Temsirolimus in Resistant Solid MalignanciesCompletedNCT00703170Phase 1
• Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal DoxorubicinTerminatedNCT00691912Phase 2
• Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing SurgeryStatus unknownNCT00671476Not applicable
• CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based ChemotherapyTerminatedNCT00653952Phase 3
• Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing RegimensWithdrawnNCT00610792Phase 2
• Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell LymphomaCompletedNCT00575406Phase 2
• Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 YearsCompletedNCT00563953Phase 2
• A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma PatientsCompletedNCT00561743Phase 2
• Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)CompletedNCT00538603Not applicable
• A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler ImagingStatus unknownNCT00531973Phase 4
• Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian CancerCompletedNCT00523380Phase 2
• Phase II Study in Patients With Operable Breast CancerStatus unknownNCT00518583Phase 2
• A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple MyelomaWithdrawnNCT00516191Phase 1/2
• Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver InvolvementCompletedNCT00507962Phase 1
• Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer PatientsCompletedNCT00500422Phase 1
• Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast CancerTerminatedNCT00465673Phase 2
• CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast CancerWithdrawnNCT00434031Phase 2
• Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast CancerTerminatedNCT00431795Phase 2

← Liposomal doxorubicin overview